CN114129479A - Composition for effectively and rapidly relieving infant dry eczema and preparation method and application thereof - Google Patents
Composition for effectively and rapidly relieving infant dry eczema and preparation method and application thereof Download PDFInfo
- Publication number
- CN114129479A CN114129479A CN202111467494.0A CN202111467494A CN114129479A CN 114129479 A CN114129479 A CN 114129479A CN 202111467494 A CN202111467494 A CN 202111467494A CN 114129479 A CN114129479 A CN 114129479A
- Authority
- CN
- China
- Prior art keywords
- phase
- parts
- composition
- effectively
- ceramide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 90
- 206010014190 Eczema asteatotic Diseases 0.000 title claims abstract description 30
- 238000002360 preparation method Methods 0.000 title claims abstract description 25
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 36
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract description 36
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 28
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims abstract description 24
- AERBNCYCJBRYDG-UHFFFAOYSA-N D-ribo-phytosphingosine Natural products CCCCCCCCCCCCCCC(O)C(O)C(N)CO AERBNCYCJBRYDG-UHFFFAOYSA-N 0.000 claims abstract description 21
- AERBNCYCJBRYDG-KSZLIROESA-N phytosphingosine Chemical compound CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@@H](N)CO AERBNCYCJBRYDG-KSZLIROESA-N 0.000 claims abstract description 21
- 229940033329 phytosphingosine Drugs 0.000 claims abstract description 21
- 235000015112 vegetable and seed oil Nutrition 0.000 claims abstract description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 20
- 235000012000 cholesterol Nutrition 0.000 claims abstract description 18
- 240000001548 Camellia japonica Species 0.000 claims abstract description 17
- 239000011347 resin Substances 0.000 claims abstract description 17
- 229920005989 resin Polymers 0.000 claims abstract description 17
- BBAFBDLICMHBNU-MFZOPHKMSA-N N-(2-hydroxyoctadecanoyl)-4-hydroxysphinganine Chemical compound CCCCCCCCCCCCCCCCC(O)C(=O)N[C@@H](CO)[C@H](O)[C@H](O)CCCCCCCCCCCCCC BBAFBDLICMHBNU-MFZOPHKMSA-N 0.000 claims abstract description 16
- ATGQXSBKTQANOH-UWVGARPKSA-N N-oleoylphytosphingosine Chemical compound CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@H](CO)NC(=O)CCCCCCC\C=C/CCCCCCCC ATGQXSBKTQANOH-UWVGARPKSA-N 0.000 claims abstract description 16
- GCDXVKZXCQGDHC-BLCQCPAESA-N [30-oxo-30-[[(2s,3s,4r)-1,3,4-trihydroxyoctadecan-2-yl]amino]triacontyl] (9z,12z)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@H](CO)NC(=O)CCCCCCCCCCCCCCCCCCCCCCCCCCCCCOC(=O)CCCCCCC\C=C/C\C=C/CCCCC GCDXVKZXCQGDHC-BLCQCPAESA-N 0.000 claims abstract description 16
- 229940086668 ceramide eop Drugs 0.000 claims abstract description 16
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims abstract description 15
- 235000018597 common camellia Nutrition 0.000 claims abstract description 13
- 229940015975 1,2-hexanediol Drugs 0.000 claims abstract description 12
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims abstract description 12
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000004475 Arginine Substances 0.000 claims abstract description 12
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract description 12
- 235000021314 Palmitic acid Nutrition 0.000 claims abstract description 12
- 229920002125 Sokalan® Polymers 0.000 claims abstract description 12
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229960001631 carbomer Drugs 0.000 claims abstract description 12
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229940067606 lecithin Drugs 0.000 claims abstract description 12
- 235000010445 lecithin Nutrition 0.000 claims abstract description 12
- 239000000787 lecithin Substances 0.000 claims abstract description 12
- 229940016286 microcrystalline cellulose Drugs 0.000 claims abstract description 12
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract description 12
- 239000008108 microcrystalline cellulose Substances 0.000 claims abstract description 12
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims abstract description 12
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims abstract description 12
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims abstract description 12
- NTYZDAJPNNBYED-UHFFFAOYSA-M sodium;2-(2-dodecanoyloxypropanoyloxy)propanoate Chemical compound [Na+].CCCCCCCCCCCC(=O)OC(C)C(=O)OC(C)C([O-])=O NTYZDAJPNNBYED-UHFFFAOYSA-M 0.000 claims abstract description 12
- 229930003799 tocopherol Natural products 0.000 claims abstract description 12
- 229960001295 tocopherol Drugs 0.000 claims abstract description 12
- 239000011732 tocopherol Substances 0.000 claims abstract description 12
- 235000010384 tocopherol Nutrition 0.000 claims abstract description 12
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 claims abstract description 12
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims abstract description 12
- NKEQOUMMGPBKMM-UHFFFAOYSA-N 2-hydroxy-2-[2-(2-hydroxy-3-octadecanoyloxypropoxy)-2-oxoethyl]butanedioic acid Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CC(O)(C(O)=O)CC(O)=O NKEQOUMMGPBKMM-UHFFFAOYSA-N 0.000 claims abstract description 9
- ANZUDYZHSVGBRF-UHFFFAOYSA-N 3-ethylnonane-1,2,3-triol Chemical compound CCCCCCC(O)(CC)C(O)CO ANZUDYZHSVGBRF-UHFFFAOYSA-N 0.000 claims abstract description 9
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229940081733 cetearyl alcohol Drugs 0.000 claims abstract description 9
- 229940075529 glyceryl stearate Drugs 0.000 claims abstract description 9
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 8
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000011709 vitamin E Substances 0.000 claims abstract description 8
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 8
- 229940046009 vitamin E Drugs 0.000 claims abstract description 8
- 239000006071 cream Substances 0.000 claims abstract description 7
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims abstract description 4
- 241001092489 Potentilla Species 0.000 claims abstract description 4
- 229960003121 arginine Drugs 0.000 claims abstract description 4
- 229960005150 glycerol Drugs 0.000 claims abstract description 4
- 239000013521 mastic Substances 0.000 claims abstract description 4
- 229940098695 palmitic acid Drugs 0.000 claims abstract description 4
- 240000007551 Boswellia serrata Species 0.000 claims description 15
- 235000012035 Boswellia serrata Nutrition 0.000 claims description 15
- 238000001816 cooling Methods 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 14
- 206010014198 Eczema infantile Diseases 0.000 claims description 13
- 201000008937 atopic dermatitis Diseases 0.000 claims description 13
- 239000002994 raw material Substances 0.000 claims description 13
- 238000010438 heat treatment Methods 0.000 claims description 12
- 238000003756 stirring Methods 0.000 claims description 11
- 229940064064 purslane extract Drugs 0.000 claims description 9
- -1 vitamin E Chemical compound 0.000 claims description 8
- 230000001804 emulsifying effect Effects 0.000 claims description 6
- 229940088594 vitamin Drugs 0.000 claims description 6
- 229930003231 vitamin Natural products 0.000 claims description 6
- 239000011782 vitamin Substances 0.000 claims description 6
- 235000013343 vitamin Nutrition 0.000 claims description 6
- 238000005303 weighing Methods 0.000 claims description 6
- 239000010487 meadowfoam seed oil Substances 0.000 claims description 5
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 5
- 239000010495 camellia oil Substances 0.000 claims description 4
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 3
- NCZPCONIKBICGS-UHFFFAOYSA-N 3-(2-ethylhexoxy)propane-1,2-diol Chemical compound CCCCC(CC)COCC(O)CO NCZPCONIKBICGS-UHFFFAOYSA-N 0.000 claims description 3
- 244000261559 Smilax china Species 0.000 claims description 3
- 235000000485 Smilax china Nutrition 0.000 claims description 3
- HFJHNGKIVAKCIW-UHFFFAOYSA-N Stearyl monoglyceridyl citrate Chemical compound OCC(O)CO.OC(=O)CC(O)(CC(O)=O)CC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O HFJHNGKIVAKCIW-UHFFFAOYSA-N 0.000 claims description 3
- 229940082500 cetostearyl alcohol Drugs 0.000 claims description 3
- 229940100524 ethylhexylglycerin Drugs 0.000 claims description 3
- 235000021384 green leafy vegetables Nutrition 0.000 claims description 3
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 claims description 3
- 210000003491 skin Anatomy 0.000 description 47
- 201000004624 Dermatitis Diseases 0.000 description 15
- 208000010668 atopic eczema Diseases 0.000 description 13
- 239000000047 product Substances 0.000 description 12
- 208000003251 Pruritus Diseases 0.000 description 11
- 206010040844 Skin exfoliation Diseases 0.000 description 7
- 230000035618 desquamation Effects 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 208000010201 Exanthema Diseases 0.000 description 5
- 244000234609 Portulaca oleracea Species 0.000 description 5
- 235000001855 Portulaca oleracea Nutrition 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- 201000005884 exanthem Diseases 0.000 description 5
- 230000003020 moisturizing effect Effects 0.000 description 5
- 206010037844 rash Diseases 0.000 description 5
- 230000008439 repair process Effects 0.000 description 5
- 230000008591 skin barrier function Effects 0.000 description 5
- 235000006467 Camellia japonica Nutrition 0.000 description 4
- 206010020751 Hypersensitivity Diseases 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 208000028990 Skin injury Diseases 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 208000026935 allergic disease Diseases 0.000 description 4
- 230000007815 allergy Effects 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- 241001480043 Arthrodermataceae Species 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- 239000004909 Moisturizer Substances 0.000 description 2
- 241001122767 Theaceae Species 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 238000003287 bathing Methods 0.000 description 2
- 230000032677 cell aging Effects 0.000 description 2
- 230000019522 cellular metabolic process Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000037304 dermatophytes Effects 0.000 description 2
- 230000037336 dry skin Effects 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 230000001333 moisturizer Effects 0.000 description 2
- 210000002464 muscle smooth vascular Anatomy 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- 230000005808 skin problem Effects 0.000 description 2
- 230000036555 skin type Effects 0.000 description 2
- PEYUIKBAABKQKQ-AFHBHXEDSA-N (+)-sesamin Chemical compound C1=C2OCOC2=CC([C@H]2OC[C@H]3[C@@H]2CO[C@@H]3C2=CC=C3OCOC3=C2)=C1 PEYUIKBAABKQKQ-AFHBHXEDSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 241000717739 Boswellia sacra Species 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000004863 Frankincense Substances 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 150000001783 ceramides Chemical class 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- PEYUIKBAABKQKQ-UHFFFAOYSA-N epiasarinin Natural products C1=C2OCOC2=CC(C2OCC3C2COC3C2=CC=C3OCOC3=C2)=C1 PEYUIKBAABKQKQ-UHFFFAOYSA-N 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- VRMHCMWQHAXTOR-CMOCDZPBSA-N sesamin Natural products C1=C2OCOC2=CC([C@@H]2OC[C@@]3(C)[C@H](C=4C=C5OCOC5=CC=4)OC[C@]32C)=C1 VRMHCMWQHAXTOR-CMOCDZPBSA-N 0.000 description 1
- 244000005714 skin microbiome Species 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/41—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/68—Sphingolipids, e.g. ceramides, cerebrosides, gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses a composition for effectively and rapidly relieving dry eczema of infants, and a preparation method and application thereof. Phase A comprises water, glycerol, 1, 2-hexanediol, carbomer, and arginine; the phase B comprises camellia seed oil, caprylic/capric triglyceride, polyglycerol-3-methylglucose distearate, cetearyl alcohol, palmitic acid, glyceryl stearate citrate, glyceryl stearate, tocopherol (vitamin E), and white Potentilla seed oil; the phase C comprises herba Portulacae extract, butanediol, phytosphingosine, cholesterol, sodium lauroyl lactylate, ethylhexyl glycerol, ceramide NP, ceramide EOP, ceramide AP, lecithin, mastic resin extract of folium Osmanthi Fragrantis, and microcrystalline cellulose. The invention also provides a preparation method and application of the composition. The composition is used for preparing infant cream. The composition prepared by the invention can effectively and quickly relieve dry eczema for all skins of infants.
Description
Technical Field
The invention relates to a formula composition for effectively relieving infant eczema sicca in the field of cosmetics, a preparation method and application thereof, and particularly relates to a composition for effectively and quickly relieving infant eczema sicca, a preparation method and application thereof.
Background
In the growing process of babies, a father baby and a mother baby are worried about suffering from dry eczema. Eczema sicca is also known as fatty eczema and is mainly affected by factors such as familial heredity and seasonal factors. Wherein the family genetic factors are commonly found in infants; meanwhile, the skin is dried in autumn and winter, so that the skin is less nourished, the skin lipid film becomes thin, and the skin is dried and desquamated, and the dry eczema is formed. In addition, many infants have dry skin, desquamation, pruritus and other symptoms due to hypoevolutism of sebaceous glands or excessive bathing and insufficient secretion of oil.
For infants with dry eczema, dad should first avoid external stimulation, pay attention to the change of body temperature of the infants and pay attention to the change of air humidity. Meanwhile, the skin of the baby should be kept clean and dry, and the skin moisturizing lotion is adopted after bathing, so that the water-oil balance of the skin of the baby is improved. However, the skin moistening and moisturizing lotions on the market at present are uneven in level, the safety is difficult to guarantee, and a natural composition aiming at dry eczema is also lacked.
Disclosure of Invention
The invention aims to provide a formula composition suitable for infants to effectively relieve eczema sicca, a preparation method thereof and application of the formula composition in skin care products, which can solve the existing problems and effectively and quickly relieve eczema sicca for all skin types of infants.
In order to achieve the above object, the present invention provides a composition for effectively and rapidly relieving infantile eczema sicca, wherein the composition comprises a phase a, a phase B, a phase C; phase A comprises water, glycerol, 1, 2-hexanediol, carbomer, and arginine; the phase B comprises camellia seed oil, caprylic/capric triglyceride, polyglycerol-3-methylglucose distearate, cetearyl alcohol, palmitic acid, glyceryl stearate citrate, glyceryl stearate, tocopherol (vitamin E), and white Potentilla seed oil; the phase C comprises herba Portulacae extract, butanediol, phytosphingosine, cholesterol, sodium lauroyl lactylate, ethylhexyl glycerol, ceramide NP, ceramide EOP, ceramide AP, lecithin, mastic resin extract of folium Osmanthi Fragrantis, and microcrystalline cellulose.
The composition for effectively and rapidly relieving dry eczema of infants comprises the following components in parts by weight: phase A, 2.8-3.3 parts of glycerol, 2.8-3.3 parts of 1, 2-hexanediol, 0.04-0.08 part of carbomer and 0.8-1.2 parts of arginine; phase B, 4.5-5.4 parts of camellia oil, 2.8-3.3 parts of caprylic/capric triglyceride, 2.8-3.3 parts of polyglycerol-3-methyl glucose distearate, 2.8-3.3 parts of cetostearyl alcohol, 2.8-3.3 parts of palmitic acid, 1.6-2.2 parts of glycerol stearate citrate, 0.8-1.2 parts of glycerol stearate, 4.5-5.4 parts of tocopherol, namely vitamin E, and 4.5-5.4 parts of chinaroot greens seed oil; phase C, 4.5-5.4 parts of purslane extract, 2.8-3.3 parts of butanediol, 4.5-5.4 parts of phytosphingosine, 4.5-5.4 parts of cholesterol, 0.8-1.2 parts of sodium lauroyl lactylate, 4.5-5.4 parts of ethylhexyl glycerol, 4.5-5.4 parts of ceramide NP, 4.5-5.4 parts of ceramide EOP, 4.5-5.4 parts of ceramide AP, 4.5-5.4 parts of lecithin, 9.5-10.5 parts of boswellia serrata resin extract and 0.05-0.2 part of microcrystalline cellulose.
The composition for effectively and rapidly relieving dry eczema of infants is prepared by adding water to 100 parts by weight.
The composition for effectively and rapidly relieving infantile eczema sicca comprises the following components in percentage by mass: phase A, 3% of glycerol, 3% of 1, 2-hexanediol, 0.05% of carbomer and 1% of arginine; phase B, camellia seed oil 5%, caprylic/capric triglyceride 3%, polyglyceryl-3-methylglucose distearate 3%, cetearyl alcohol 3%, palmitic acid 3%, glyceryl stearate citrate 2%, glyceryl stearate 1%, tocopherol, i.e. vitamin E5%, meadowfoam seed oil 5%; phase C, purslane extract 5%, butylene glycol 3%, phytosphingosine 5%, cholesterol 5%, sodium lauroyl lactylate 1%, ethylhexylglycerin 5%, ceramide NP 5%, ceramide EOP 5%, ceramide AP 5%, lecithin 5%, boswellia serrata resin extract 10%, and microcrystalline cellulose 0.1%.
The composition for effectively and rapidly relieving dry eczema in infants is prepared by adding water to 100% by mass.
The invention also provides a preparation method of the composition for effectively and rapidly relieving infantile eczema sicca, wherein the method comprises the following steps: step 1, weighing raw materials in proportion, and dividing the raw materials into a phase A, a phase B and a phase C; step 2, heating the phase A to be completely dissolved; step 3, heating the phase B until the phase B is completely dissolved, adding the phase B into the phase A, and emulsifying; step 4, cooling the obtained mixture, adding the phase C, and uniformly stirring; and 5, continuously cooling to finish the preparation of the composition.
In the step 3, after the phase B is heated to be completely dissolved, the phase B is added into the phase A and emulsified for 5 minutes.
In the step 4, the mixture is cooled to 40 ℃, and then the phase C is added.
In the above preparation method of the composition for effectively and rapidly relieving infantile eczema, in the step 5, the mixture is continuously stirred and cooled to room temperature, so that the preparation of the composition is completed.
The invention also provides the application of the composition prepared by the method for effectively and rapidly relieving the dry eczema of the infant, wherein the composition is used for preparing a skin care product; the skin care product comprises baby cream.
The composition for effectively and rapidly relieving dry eczema of infants, the preparation method and the application provided by the invention have the following advantages:
the composition disclosed by the invention is prepared by combining BOSWELLIA SERRATA (BOSWELLIA SERRATA) resin extract, ceramide NP/ceramide EOP/ceramide AP, phytosphingosine/cholesterol composition, purslane (PORTULACA OLERACEA) extract, CAMELLIA (CAMELLIA JAPONICA) seed oil and the like for the first time. The obtained composition can effectively and rapidly relieve various symptoms of dryness, itching, damage, redness, stabbing pain, rash and the like caused by infant eczema sicca aiming at all skin types of infants, and rapidly repair skin barriers, thereby repairing the skin immune system of the infants.
The composition can rapidly improve symptoms such as sensitive roughness, acne, red blood streak, desquamation, pruritus and the like caused by dry skin, and has the effects of repairing skin barriers, supplementing water, moistening skin, moisturizing and locking water, relieving allergy, resisting inflammation, delaying aging and the like, thereby effectively relieving skin sensitive eczema, eliminating pox, reducing red blood streak, improving desquamation and the like.
Detailed Description
The following further describes embodiments of the present invention.
The composition for effectively and rapidly relieving the dry eczema in the infant comprises a phase A, a phase B and a phase C; phase A comprises water, glycerol, 1, 2-hexanediol, carbomer, and arginine; the phase B comprises camellia seed oil, caprylic/capric triglyceride, polyglycerol-3-methylglucose distearate, cetearyl alcohol, palmitic acid, glyceryl stearate citrate, glyceryl stearate, tocopherol (vitamin E), and white Potentilla seed oil; the phase C comprises herba Portulacae extract, butanediol, phytosphingosine, cholesterol, sodium lauroyl lactylate, ethylhexyl glycerol, ceramide NP, ceramide EOP, ceramide AP, lecithin, mastic resin extract of folium Osmanthi Fragrantis, and microcrystalline cellulose.
Preferably, the composition comprises the following components in parts by weight: phase A, 2.8-3.3 parts of glycerol, 2.8-3.3 parts of 1, 2-hexanediol, 0.04-0.08 part of carbomer and 0.8-1.2 parts of arginine; phase B, 4.5-5.4 parts of camellia oil, 2.8-3.3 parts of caprylic/capric triglyceride, 2.8-3.3 parts of polyglycerol-3-methyl glucose distearate, 2.8-3.3 parts of cetostearyl alcohol, 2.8-3.3 parts of palmitic acid, 1.6-2.2 parts of glycerol stearate citrate, 0.8-1.2 parts of glycerol stearate, 4.5-5.4 parts of tocopherol, namely vitamin E, and 4.5-5.4 parts of chinaroot greens seed oil; phase C, 4.5-5.4 parts of purslane extract, 2.8-3.3 parts of butanediol, 4.5-5.4 parts of phytosphingosine, 4.5-5.4 parts of cholesterol, 0.8-1.2 parts of sodium lauroyl lactylate, 4.5-5.4 parts of ethylhexyl glycerol, 4.5-5.4 parts of ceramide NP, 4.5-5.4 parts of ceramide EOP, 4.5-5.4 parts of ceramide AP, 4.5-5.4 parts of lecithin, 9.5-10.5 parts of boswellia serrata resin extract and 0.05-0.2 part of microcrystalline cellulose.
The composition is added with water to 100 parts by weight.
More preferably, the composition comprises the following components in percentage by mass: phase A, 3% of glycerol, 3% of 1, 2-hexanediol, 0.05% of carbomer and 1% of arginine; phase B, camellia seed oil 5%, caprylic/capric triglyceride 3%, polyglyceryl-3-methylglucose distearate 3%, cetearyl alcohol 3%, palmitic acid 3%, glyceryl stearate citrate 2%, glyceryl stearate 1%, tocopherol, i.e. vitamin E5%, meadowfoam seed oil 5%; phase C, purslane extract 5%, butylene glycol 3%, phytosphingosine 5%, cholesterol 5%, sodium lauroyl lactylate 1%, ethylhexylglycerin 5%, ceramide NP 5%, ceramide EOP 5%, ceramide AP 5%, lecithin 5%, boswellia serrata resin extract 10%, and microcrystalline cellulose 0.1%.
The composition is added with water to 100 percent by mass percent.
The main functional components of the composition of the invention are as follows: olibanum resin extract (Boswellia SERRATA), ceramide NP/ceramide EOP/ceramide AP, phytosphingosine/cholesterol composition, herba Portulacae (Portulaca OLERACEA) extract, and herba Camelliae Japonicae (Camellia JAPONICA) seed oil.
The BOSWELLIA SERRATA (BOSWELLIA SERRATA) resin extract is extracted from BOSWELLIA SERRATA resin, is a natural inflammation treatment substance, and can rapidly heal skin injury and repair skin barrier by activating a peroxidase to activate a receptor; promoting activation of caspase, prolonging skin cell life, and relieving cell aging. It has high safety and is widely used for pregnant women and infant products.
The ceramide NP/ceramide EOP/ceramide AP are various ceramide compounds, can be cooperated with natural protective barriers of the skin, can promote the water absorption of the skin, prevent the water loss of the skin and resist external influence, improve the autoimmune system, eliminate skin inflammation, have stronger oxidation resistance, and can relieve the symptoms of skin injury and the like.
Phytosphingosine/cholesterol compositions, in which phytosphingosine is a precursor to phospholipids, more closely related to skin lipids, are important components of moisture retention and barrier function. The phytosphingosine is one of important oil components in human epidermis, the reduction of the phytosphingosine can cause dry and rough skin, and the phytosphingosine can effectively keep the skin soft and moist and protect the cortex; phytosphingosine has antibacterial and antiinflammatory effects; cholesterol and derivatives thereof are inherent components of the skin, have no stimulation to the skin and have high safety; cholesterol has anti-inflammatory and moisturizing effects, and can promote absorption of effective components.
The herba Portulacae (Portulaca OLERACEA) extract contains abundant plant polysaccharides and vitamins, and has effects of moistening skin, promoting epithelial cell metabolism, and relieving desquamation and pruritus caused by dryness; simultaneously contains various amino acids, can shrink vascular smooth muscle, has the central and peripheral properties of contraction, and can relieve skin and inhibit skin pruritus caused by dryness; the herba Portulacae (Portulaca OLERACEA) extract also contains a large amount of alkaloids and flavones, and can be used for inhibiting bacteria and common pathogenic dermatophytes.
Camellia (Camellia JAPONICA) seed oil is extracted from CAMELLIA JAPONICA flower, leaf and seed, is natural component, has high safety, and can be used for pregnant women and infants. The camellia seed oil contains various unsaturated fatty acids, has good skin compatibility, is easy to be absorbed by the skin, contains more components such as tea polyphenol, camellia sesamin, tea saponin and the like, has extremely high vitamin E content and anti-inflammatory property, and can effectively treat skin problems such as allergy, rash, eczema and the like.
The invention also provides a preparation method of the composition for effectively and rapidly relieving the dry eczema of the infant, which comprises the following steps: step 1, weighing raw materials in proportion, and dividing the raw materials into a phase A, a phase B and a phase C; step 2, heating the phase A to be completely dissolved; step 3, heating the phase B until the phase B is completely dissolved, adding the phase B into the phase A, and emulsifying; step 4, cooling the obtained mixture, adding the phase C, and uniformly stirring; and 5, continuously cooling to finish the preparation of the composition.
In step 3, the phase B is heated to be completely dissolved, and then added into the phase A to be emulsified for 5 minutes.
In step 4, the mixture is cooled to 40 ℃ and then phase C is added.
And step 5, continuously stirring and cooling to room temperature to finish the preparation of the composition.
The invention also provides the application of the composition prepared by the method, which is used for preparing a skin care product and is effective in rapidly relieving infantile eczema sicca; the skin care product comprises baby cream.
The following examples are provided to further describe the composition for effectively and rapidly relieving infantile eczema sicca, the preparation method and the use thereof.
Example 1
A composition for effectively and rapidly relieving dry eczema in infants is shown in the following table 1.
All the raw materials respectively accord with the corresponding national standards.
Table 1 composition formulation table (in mass percent).
The embodiment also provides a preparation method of the composition for effectively and rapidly relieving infantile eczema sicca, which comprises the following steps:
step 1, weighing the raw materials in proportion, and dividing the raw materials into a phase A, a phase B and a phase C.
And 2, heating the phase A until the phase A is completely dissolved.
And 3, heating the phase B until the phase B is completely dissolved, adding the phase A into the phase B, and emulsifying for 5 minutes.
And 4, cooling the obtained mixture to 40 ℃, adding the phase C, and uniformly stirring.
And 5, continuously stirring and cooling to room temperature to finish the preparation of the composition.
The embodiment also provides the application of the composition prepared by the method, which is used for preparing the skin care product and is effective in rapidly relieving the dry eczema of the infant; the skin care product comprises baby cream.
Example 2
A composition for rapidly and effectively relieving infantile eczema sicca comprises phase A, phase B and phase C.
Preferably, the composition comprises the following components in parts by weight:
phase A, 2.8 parts of glycerol, 2.8 parts of 1, 2-hexanediol, 0.04 part of carbomer and 0.8 part of arginine.
Phase B, camellia seed oil 4.5 parts, caprylic/capric triglyceride 2.8 parts, polyglycerol-3-methylglucose distearate 2.8 parts, cetearyl alcohol 2.8 parts, palmitic acid 2.8 parts, glyceryl stearate citrate 1.6 parts, glyceryl stearate 0.8 part, tocopherol, namely vitamin E4.5 parts, and meadowfoam seed oil 4.5 parts.
Phase C, purslane extract 4.5 parts, butanediol 2.8 parts, phytosphingosine 4.5 parts, cholesterol 4.5 parts, sodium lauroyl lactylate 0.8 part, ethylhexyl glycerol 4.5 parts, ceramide NP 4.5 parts, ceramide EOP 4.5 parts, ceramide AP 4.5 parts, lecithin 4.5 parts, boswellia serrata resin extract 9.5 parts, and microcrystalline cellulose 0.05 part.
Further, water is added to the composition to 100 parts by weight.
The embodiment also provides a preparation method of the composition for effectively and rapidly relieving infantile eczema sicca, which comprises the following steps:
step 1, weighing the raw materials in proportion, and dividing the raw materials into a phase A, a phase B and a phase C.
And 2, heating the phase A until the phase A is completely dissolved.
And 3, heating the phase B until the phase B is completely dissolved, adding the phase A into the phase B, and emulsifying for 5 minutes.
And 4, cooling the obtained mixture to 40 ℃, adding the phase C, and uniformly stirring.
And 5, continuously stirring and cooling to room temperature to finish the preparation of the composition.
The embodiment also provides the application of the composition prepared by the method, which is used for preparing the skin care product and is effective in rapidly relieving the dry eczema of the infant; the skin care product comprises baby cream.
Example 3
A composition for rapidly and effectively relieving infantile eczema sicca comprises phase A, phase B and phase C.
Preferably, the composition comprises the following components in parts by weight:
phase A, 3.3 parts of glycerol, 3.3 parts of 1, 2-hexanediol, 0.08 part of carbomer and 1.2 parts of arginine.
Phase B, camellia seed oil 5.4 parts, caprylic/capric triglyceride 3.3 parts, polyglycerol-3-methylglucose distearate 3.3 parts, cetearyl alcohol 3.3 parts, palmitic acid 3.3 parts, glyceryl stearate citrate 2.2 parts, glyceryl stearate 1.2 parts, tocopherol, namely vitamin E5.4 parts, and meadowfoam seed oil 5.4 parts.
Phase C, purslane extract 5.4 parts, butanediol 3.3 parts, phytosphingosine 5.4 parts, cholesterol 5.4 parts, sodium lauroyl lactylate 1.2 parts, ethylhexyl glycerol 5.4 parts, ceramide NP 5.4 parts, ceramide EOP 5.4 parts, ceramide AP 5.4 parts, lecithin 5.4 parts, boswellia serrata resin extract 10.5 parts, and microcrystalline cellulose 0.2 part.
Further, water is added to the composition to 100 parts by weight.
The embodiment also provides a preparation method of the composition for effectively and rapidly relieving infantile eczema sicca, which comprises the following steps:
step 1, weighing the raw materials in proportion, and dividing the raw materials into a phase A, a phase B and a phase C.
And 2, heating the phase A until the phase A is completely dissolved.
And 3, heating the phase B until the phase B is completely dissolved, adding the phase A into the phase B, and emulsifying for 5 minutes.
And 4, cooling the obtained mixture to 40 ℃, adding the phase C, and uniformly stirring.
And 5, continuously stirring and cooling to room temperature to finish the preparation of the composition.
The embodiment also provides the application of the composition prepared by the method, which is used for preparing the skin care product and is effective in rapidly relieving the dry eczema of the infant; the skin care product comprises baby cream.
The compositions prepared in the examples were tested and evaluated in the following manner.
1. The person to be tested.
Experimental group (invention): 25, 12 men and 13 women; the age is 5-47 months.
Control group (placebo-general moisturizer): 25, 13 men and 12 women, age 4-46 months.
The data of sex, age, etc. of two groups of people are statistically processed, the difference is not statistically significant (P >0.05), and the two groups are comparable.
2. The use method comprises the following steps: the composition of each example of the invention was applied to the eczema sites of the experimental groups, the ordinary moisturizers were applied to the eczema sites of the control groups, and the skin repair time was recorded and evaluated as follows, and the occurrence of adverse reactions was recorded.
3. Evaluation criteria: the evaluation was made based on the condition of dry, itchy, damaged, red, prickled, rash, etc.
And (3) healing: the symptoms and signs are resolved by more than 95%.
The effect is shown: the clinical manifestation is reduced by 80 to 94 percent.
Improvement: clinical performance is reduced by 50-79%.
And (4) invalidation: no improvement in clinical manifestations.
4. As a result: the results are shown in table 2 below.
Table 2. experimental results.
The difference analysis (P is less than 0.05) of the experimental group and the control group has obvious difference, and the statistical significance is achieved. The effective rate of the experimental group is obviously higher than that of the control group, which shows that the experimental group can quickly and effectively relieve the symptoms of dryness, itching, breakage, redness, stabbing pain, rash and the like of the infant caused by the dry eczema, and various uncomfortable feelings can not be generated, thus the invention has good effect.
The composition for effectively and quickly relieving the dry eczema of the infants, the preparation method and the application can effectively and quickly relieve the dry eczema, relieve the skin sensitivity, improve the stable state of skin flora and effectively improve the symptoms of sensitive and rough skin, acne, red blood streak, desquamation, pruritus and the like aiming at all the skins of the infants.
In the components of the composition, the boswellia serrata resin extract has higher safety and can quickly heal skin injury and repair skin barriers; prolonging skin cell life, and relieving cell aging. The ceramide NP/ceramide EOP/ceramide AP can play a synergistic role with skin, promote water absorption, prevent water loss, resist external stimulation, improve an autoimmune system, eliminate skin inflammation and relieve skin injury. The phytosphingosine can keep skin soft and moist, protect cortex, and resist bacteria and inflammation; cholesterol and its derivatives are safe and non-irritating to the skin, have anti-inflammatory and moisturizing effects, and promote the absorption of active substances. The purslane extract can moisten skin, promote epithelial cell metabolism and relieve symptoms such as desquamation, pruritus and the like caused by dryness; contracting vascular smooth muscle and relieving skin pruritus; simultaneously has the functions of resisting bacteria and inhibiting common pathogenic dermatophytes. The camellia oil has high safety and anti-inflammatory property, and can effectively treat skin problems such as allergy, rash, eczema and the like.
The composition has high safety, can be used for pregnant women and infants, and can quickly relieve dryness of skin of infants, repair skin barrier, supplement water, moisten skin, keep moisture and lock water, relieve allergy and inflammation, and relieve pruritus, thereby effectively relieving skin sensitive eczema, eliminating pox, reducing red blood streak, and improving desquamation.
While the present invention has been described in detail with reference to the preferred embodiments, it should be understood that the above description should not be taken as limiting the invention. Various modifications and alterations to this invention will become apparent to those skilled in the art upon reading the foregoing description. Accordingly, the scope of the invention should be determined from the following claims.
Claims (10)
1. A composition for effectively and rapidly relieving dry eczema in infants is characterized by comprising a phase A, a phase B and a phase C;
phase A comprises water, glycerol, 1, 2-hexanediol, carbomer, and arginine;
the phase B comprises camellia seed oil, caprylic/capric triglyceride, polyglycerol-3-methylglucose distearate, cetearyl alcohol, palmitic acid, glyceryl stearate citrate, glyceryl stearate, tocopherol (vitamin E), and white Potentilla seed oil;
the phase C comprises herba Portulacae extract, butanediol, phytosphingosine, cholesterol, sodium lauroyl lactylate, ethylhexyl glycerol, ceramide NP, ceramide EOP, ceramide AP, lecithin, mastic resin extract of folium Osmanthi Fragrantis, and microcrystalline cellulose.
2. The composition for effectively and rapidly relieving dry eczema in infants according to claim 1, wherein the composition comprises the following components in parts by weight:
phase A, 2.8-3.3 parts of glycerol, 2.8-3.3 parts of 1, 2-hexanediol, 0.04-0.08 part of carbomer and 0.8-1.2 parts of arginine;
phase B, 4.5-5.4 parts of camellia oil, 2.8-3.3 parts of caprylic/capric triglyceride, 2.8-3.3 parts of polyglycerol-3-methyl glucose distearate, 2.8-3.3 parts of cetostearyl alcohol, 2.8-3.3 parts of palmitic acid, 1.6-2.2 parts of glycerol stearate citrate, 0.8-1.2 parts of glycerol stearate, 4.5-5.4 parts of tocopherol, namely vitamin E, and 4.5-5.4 parts of chinaroot greens seed oil;
phase C, 4.5-5.4 parts of purslane extract, 2.8-3.3 parts of butanediol, 4.5-5.4 parts of phytosphingosine, 4.5-5.4 parts of cholesterol, 0.8-1.2 parts of sodium lauroyl lactylate, 4.5-5.4 parts of ethylhexyl glycerol, 4.5-5.4 parts of ceramide NP, 4.5-5.4 parts of ceramide EOP, 4.5-5.4 parts of ceramide AP, 4.5-5.4 parts of lecithin, 9.5-10.5 parts of boswellia serrata resin extract and 0.05-0.2 part of microcrystalline cellulose.
3. The composition for effectively and rapidly relieving dry eczema in infants according to claim 2, wherein the composition is prepared by adding water to 100 parts by weight.
4. The composition for effectively and rapidly relieving infantile eczema sicca according to claim 2, wherein the composition comprises the following components in percentage by mass:
phase A, 3% of glycerol, 3% of 1, 2-hexanediol, 0.05% of carbomer and 1% of arginine;
phase B, camellia seed oil 5%, caprylic/capric triglyceride 3%, polyglyceryl-3-methylglucose distearate 3%, cetearyl alcohol 3%, palmitic acid 3%, glyceryl stearate citrate 2%, glyceryl stearate 1%, tocopherol, i.e. vitamin E5%, meadowfoam seed oil 5%;
phase C, purslane extract 5%, butylene glycol 3%, phytosphingosine 5%, cholesterol 5%, sodium lauroyl lactylate 1%, ethylhexylglycerin 5%, ceramide NP 5%, ceramide EOP 5%, ceramide AP 5%, lecithin 5%, boswellia serrata resin extract 10%, and microcrystalline cellulose 0.1%.
5. The composition for effectively and rapidly relieving dry eczema in infants according to claim 4, wherein the composition is added with water to 100% by mass.
6. A method for preparing a composition for effectively and rapidly relieving dry eczema in infants according to any one of claims 1 to 5, wherein the method comprises the following steps:
step 1, weighing raw materials in proportion, and dividing the raw materials into a phase A, a phase B and a phase C;
step 2, heating the phase A to be completely dissolved;
step 3, heating the phase B until the phase B is completely dissolved, adding the phase B into the phase A, and emulsifying;
step 4, cooling the obtained mixture, adding the phase C, and uniformly stirring;
and 5, continuously cooling to finish the preparation of the composition.
7. The method for preparing the composition for effectively and rapidly relieving dry eczema in infants according to claim 6, wherein in the step 3, the phase B is heated to be completely dissolved, then is added into the phase A, and is emulsified for 5 minutes.
8. The method for preparing the composition for effectively and rapidly relieving dry eczema in infants according to claim 6, wherein in the step 4, the C phase is added after the mixture is cooled to 40 ℃.
9. The method for preparing the composition for effectively and rapidly relieving infantile eczema sicca according to claim 6, wherein in the step 5, the composition is prepared by continuously stirring and cooling to room temperature.
10. Use of a composition effective in rapidly relieving dry eczema in infants prepared by the method of claim 6, in the preparation of a skin care product; the skin care product comprises baby cream.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111467494.0A CN114129479A (en) | 2021-12-03 | 2021-12-03 | Composition for effectively and rapidly relieving infant dry eczema and preparation method and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111467494.0A CN114129479A (en) | 2021-12-03 | 2021-12-03 | Composition for effectively and rapidly relieving infant dry eczema and preparation method and application thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114129479A true CN114129479A (en) | 2022-03-04 |
Family
ID=80387764
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111467494.0A Pending CN114129479A (en) | 2021-12-03 | 2021-12-03 | Composition for effectively and rapidly relieving infant dry eczema and preparation method and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114129479A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116459179A (en) * | 2023-03-20 | 2023-07-21 | 上海科黛生物科技有限公司 | Novel ceramide composition and preparation method and application thereof |
EP4356898A1 (en) * | 2022-10-20 | 2024-04-24 | Croda Korea Limited | Cosmetic composition comprising ceramides and sphingolipid |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014182031A1 (en) * | 2013-05-07 | 2014-11-13 | (주)엔제이와이생명공학 | Anti-atopic cream |
CN108567944A (en) * | 2018-07-13 | 2018-09-25 | 黄颖 | A kind of preparation method of the plant extract Chinese medicine composition of external curing eczema |
-
2021
- 2021-12-03 CN CN202111467494.0A patent/CN114129479A/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014182031A1 (en) * | 2013-05-07 | 2014-11-13 | (주)엔제이와이생명공학 | Anti-atopic cream |
CN108567944A (en) * | 2018-07-13 | 2018-09-25 | 黄颖 | A kind of preparation method of the plant extract Chinese medicine composition of external curing eczema |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4356898A1 (en) * | 2022-10-20 | 2024-04-24 | Croda Korea Limited | Cosmetic composition comprising ceramides and sphingolipid |
CN116459179A (en) * | 2023-03-20 | 2023-07-21 | 上海科黛生物科技有限公司 | Novel ceramide composition and preparation method and application thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107468621B (en) | Allergy-relieving skin-care emulsion and preparation method thereof | |
CN109044915B (en) | Infant hip-protecting cream and preparation process thereof | |
IL260028B2 (en) | Skin care preparations for babies | |
CN108542870B (en) | Mild soothing infant face cream | |
CN114129479A (en) | Composition for effectively and rapidly relieving infant dry eczema and preparation method and application thereof | |
CN111956539A (en) | Anti-allergy soothing and skin barrier repairing essence cream | |
CN113197836A (en) | Moisturizing, relieving, itching-relieving and skin-protecting cream and preparation method thereof | |
CN110179730B (en) | Repair cream | |
KR101000695B1 (en) | Cosmetic composition of natural plant mixture extracts having anti-inflammation effect | |
CN111481475A (en) | Edible lipstick capable of improving female hormone and preparation method thereof | |
KR20130015339A (en) | Cream composition for treating acne | |
CN107115347B (en) | Liposome antiallergic agent and cosmetic for repairing hormone-dependent dermatitis | |
KR20040026268A (en) | Topical composition for lowering pruritus or damaged skin barrier caused by atopic dermatitis | |
CN116889539B (en) | Composition for relieving and resisting allergy, and preparation method and application thereof | |
CN112402354A (en) | Moisturizing and moisture-preserving emulsion and preparation method thereof | |
KR101799155B1 (en) | External preparation for skin comprising extract of Traditional herb | |
CN111228154A (en) | Fresh wheat extract protoplasm milk for infants and preparation method thereof | |
KR102272771B1 (en) | Cosmetic composition for alleviating sebum secretion comprising Carthamus tinctorius extract or mixture extract of Carthamus tinctorius and Areca catechu | |
KR20080111249A (en) | A cosmetic composing chia seed extract | |
CN116115528A (en) | Composition for relieving, repairing and moisturizing as well as application and preparation method thereof | |
CN115919686A (en) | Skin soothing lotion for enhancing skin barrier and preparation method thereof | |
KR20090075950A (en) | Therapeutical compositions for obstinate atopic dermatitis | |
CN113499271A (en) | Anti-allergy compound and preparation method and application thereof | |
KR100574233B1 (en) | Cosmetic composition comprising plant extract having moisturizing and anti-irritating activity | |
CN112656728A (en) | Anti-allergy relieving liquid and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220304 |